The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to EG-501 from Evergreen Therapeutics, an investigational oral treatment for adults with cognitive impairment associated with neuropsychiatric systemic lupus erythematosus (NPSLE), following promising Phase 2 results from the ClearMEMory study. Currently, there are no approved therapies specifically targeting cognitive impairment in NPSLE. 

The 12-week, randomized, double-blind, placebo-controlled Phase 2 trial evaluated EG-501 in 56 adults with lupus-related cognitive dysfunction across three clinical sites, including Vanderbilt Health and Cleveland Clinic. Researchers assessed cognitive performance using standardized neuropsychological testing and found greater improvements among participants receiving EG-501 than among those receiving placebo. The investigational treatment works by targeting NMDA receptors, with preliminary research suggesting potential neuroprotective and anti-inflammatory effects. Detailed effect sizes and P values were not reported. 

The designation marks an encouraging regulatory step for EG-501. Evergreen Therapeutics is preparing a larger Phase 3 trial to further evaluate the treatment and confirm its potential benefits, though a timeline has not been announced. While additional research is needed to confirm the findings, the FDA's Fast Track designation could help accelerate development of a targeted treatment for lupus-related cognitive impairment, an area of significant unmet need. Learn more about neuropsychiatric lupus diagnosis and management.

Read the announcement